A stable cell line expressing KV3.1 V434L variant was developed and characterised, confirming published data describing V434L as a gain-of-function mutation.
David McCoull¹, Jonathan M Large¹, Alex Loucif², Raymond Tang², Ian Witton², Lewis Byrom¹, Edward Stevens², Jeff Jerman¹, Paul D Wright¹
Figure 1: Schematic showing the use of intracellular thallium-sensitive dye to measure ion conduction through potassium channels as a screening assay to measure the effects of modulator compounds.
Thallium Flux
APC (QPatch)
Figure 2: Schematic illustrating an automated patch clamp ‘chip’ well where cells are flowed over holes in a borosilicate substrate to obtain whole-cell access and enable patch clamp recordings of ion channel activity, and the effects of compounds added to each well (yellow).
Compound testing
Automated and Manual Patch-clamp
Correlation Between Tl+ flux and APC
Figure 5: Comparison of K2P hit compound activity obtained by thallium flux HTS assay with hit validation activity from an APC (QPatch) platform.
Figure 6: Correlation between thallium flux and APC hit compound activity is strongest for the most active compounds (bins 1-2) and for less active compounds pre-incubated in the thallium flux assay (green bars).
Compound Incubation Time
Compound Properties
A stable cell line expressing KV3.1 V434L variant was developed and characterised, confirming published data describing V434L as a gain-of-function mutation.
The development and validation of electrophysiological assays to study TRPML1 is important to understand the function and pharmacology of the channel. We used a TRPML1 variant that lacks the endo-lysosomal retention sequences (TRPML1-4A), enabling the channel to express at the plasma membrane3. As such channel behaviour can be characterised by means of whole-cell patch-clamp and fluorescence-based techniques.